About this episode

Dr. Sandra Kane-Gill discusses novel kidney biomarkers for early detection and management of drug-induced acute kidney injury.

The mortality and economic burden of drug-induced acute kidney injury are substantial, emphasizing the need for prevention and optimal treatment. Dr. Sandra Kane-Gill provides perspective on novel kidney biomarkers and how they offer a missing piece of the assessment for early detection and management of drug-induced acute kidney injury. Read the full manuscript at: https://accpjournals.onlinelibrary.wiley.com/doi/full/10.1002/phar.70071

More episodes of ACCP JOURNALS

• Navigating Cardiotoxicity in Modern Cancer Therapy - Ep 181 · April 22, 2026 · 33 min
• High-Value Interventions Primary Care Practices Might Be Overlooking: Clinical Pharmacy Services – Ep 180 · April 7, 2026 · 36 min
• Enhancing Pharmacotherapy Through Artificial Intelligence: From Prediction Models to Practice – Ep 179 · March 25, 2026 · 24 min
• A Medical Writing Rotation: Flipping the Odds on Resident Scholarship - Ep 178 · March 16, 2026 · 24 min
• Thinking Like Tree Farmers Not Muffin Makers:  Why We Need a Competency-based Framework at all Levels of Professional Education - Ep 177 · February 16, 2026 · 26 min
• An Aging HIV+ Population:  The Urgent Need (and Opportunities) for HIV-trained Pharmacists - Ep 176 · January 15, 2026 · 22 min

Explore listener stats, chart rankings, contacts and more on the ACCP JOURNALS podcast page.